IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

By sjmartinez • September 28, 2023

Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J, Lencioni R. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. PMID: 37767068; PMCID: PMC10521324.

Tags: Atezolizumab, Barcelona Clinic Liver Cancer stage B, Bevacizumab, Hematology/Oncology, Publications, unresectable

Related Posts

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee[...]

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar[...]

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin[...]